ERG antibody (AA 1-300)

Catalog No. ABIN8093156

The Mouse Monoclonal anti-ERG antibody is suitable to detect ERG in samples from Human. It has been validated for IHC.

Quick Overview for ERG antibody (AA 1-300) (ABIN8093156)

Target: ERG (ERG, ETS transcription factor (ERG))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This ERG antibody is un-conjugated

Application: Immunohistochemistry (IHC)

Grade: Carrier-free

Clone: ERG1-12589

Product Details anti-ERG Antibody

Binding Specificity: AA 1-300

Purpose: ERG Antibody / ETS transcription factor ERG (azide and preservative free)

Immunogen: A recombinant fragment (around amino acids 1-300) of human ERG (exact sequence is proprietary) was used as the immunogen for the ERG/Prostate cancer ERG antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the ERG/Prostate cancer ERG antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C,-80 °C

Storage Comment: ERG/Prostate cancer ERG antibody with sodium azide - store at 2 to 8oC, antibody without sodium azide - store at -20 to -80oC.

Target Details for ERG

Target: ERG (ERG, ETS transcription factor (ERG))

Alternative Name: ERG

Background: ERG antibody targets ETS related gene, a nuclear transcription factor encoded by the ERG gene that is aberrantly expressed in a large subset of prostate cancers. In prostate carcinoma, ERG expression most commonly arises from gene rearrangements that place ERG under the control of androgen-responsive promoters, leading to inappropriate transcriptional activation in prostate epithelial cells. As a result, ERG antibody detection is widely used in research settings to study prostate cancer-associated transcriptional reprogramming.

In normal tissues, ERG expression is largely restricted to vascular endothelial cells and select hematopoietic populations. In contrast, nuclear ERG expression in prostate epithelial cells is considered abnormal and reflects oncogenic activation rather than normal differentiation. This distinction makes ERG antibody reagents particularly valuable for examining prostate tumor biology and for distinguishing malignant epithelial cells from surrounding benign glands in tissue-based studies.

Functionally, ERG acts as a transcriptional regulator that influences genes involved in cell migration, invasion, and survival. In prostate cancer models, ERG overexpression has been associated with altered chromatin organization and cooperation with androgen receptor signaling pathways, contributing to tumor initiation and progression. ERG antibody tools support investigations into how transcription factor dysregulation reshapes gene expression programs in prostate carcinoma.

ERG expression in prostate cancer is strongly associated with specific molecular subtypes and is frequently evaluated in the context of tumor classification and disease stratification research. Nuclear ERG positivity has been correlated with distinct histopathologic features and molecular profiles, making ERG antibody-based detection relevant for studies of prostate cancer heterogeneity and progression mechanisms.

Clone ERG1/12589 is designed to recognize ERG in research applications. ERG antibody reagents are suitable for detecting nuclear ERG expression in prostate cancer tissue samples, supporting studies focused on oncogenic transcription factor activity, prostate tumor biology, and disease-associated alterations in gene regulation.

UniProt: P11308